Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109 [PMID: 22416186 DOI: 10.3748/wjg.v18.i10.1104]
Corresponding Author of This Article
Ho Sup Lee, MD, Department of Internal Medicine, Kosin University College of Medicine, 34 Amnam-Dong, Seo-Gu, Busan 602-703, South Korea. hs52silver@gmail.com
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2012; 18(10): 1104-1109 Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Table 1 Patient baseline characteristics n (%)
Characteristics
Value
n
40
Age (yr), median (range)
55.50 (26-76)
Gender
Male
22 (55.0)
Female
18 (45.0)
Primary tumor location
Colon cancer
10 (25.0)
Rectal cancer
30 (75.0)
ECOG
0-1
31 (77.5)
≥ 2
9 (22.5)
Metastatic sites
Liver only
6 (15.0)
Lung only
4 (10.0)
Liver and lung only
8 (20.0)
2 sites, including liver or lung
6 (15.0)
2 sites, excluding liver and lung
2 (5.0)
≥ 3 sites
9 (22.5)
1 site, excluding liver and lung
5 (12.5)
Number of metastatic sites
1 site
15 (37.5)
≥ 2 sites
25 (62.5)
Histologic type
Well
9 (22.5)
Moderate
9 (22.5)
Poor
1 (2.5)
Unknown
21 (52.5)
Previous chemotherapy
Fluoropyrimidine + oxaliplatin
31
Fluoropyrimidine + irinotecan
25
Capecitabine combined
15
Fluoropyrimidine combined
6
Line number of bevacizumab
2nd line
17 (42.5)
3rd line
13 (32.5)
4th or later-line
10 (25.0)
Chemotherapy associated with bevacizumab
Oxaliplatin-combined
12 (30.0)
Irinotecan- combined
19 (47.5)
5-fluorouracil-combined
8 (20.0)
Bevacizumab alone
1 (2.5)
Table 2 Response to treatment n (%)
Response
Patients
CR
PR
SD
PD
Unknown
Overall
40
0 (0.0)
3 (7.5)
21 (52.5)
15 (37.5)
1 (2.5)
2nd line
17
0 (0.0)
2 (13.3)
11 (64.7)
4 (23.5)
0 (0.0)
3rd line
13
0 (0.0)
1 (7.7)
6 (46.2)
5 (38.5)
1 (7.7)
4th or later-line
10
0 (0.0)
0 (0.0)
4 (40.0)
6 (60.0)
0 (0.0)
Table 3 Analysis of survival
End point
Median follow-up duration (range) (mo)
mOS (95% CI) (mo)
mPFS (95% CI) (mo)
Overall
23.87 (6.13-77.83)
14.00 (7.77-20.23)
6.13 (3.94-8.33)
2nd line
22.37 (6.13-56.10)
16.60 (3.22-29.98)
7.23 (6.45-8.02)
3rd line
20.03 (13.87-57.77)
14.07 (6.89-21.25)
7.30 (3.84-10.77)
4th and later-line
51.12 (17.87-77.83)
13.00 (4.48-21.52)
3.87 (2.78-4.95)
Table 4 Summary of the data after bevacizumab-combined chemotherapy as second- and later-line treatment in patients with metastatic colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
Citation: Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109